Bi-213 is an attractive alpha-emitter for targeted radiotherapy of cancer. It is commonly introduced into small peptides via a DOTA complex, and into antibodies via CHX-A-DTPA. We investigated Bi-213-labeling efficiency, kinetics and stability of phosphonic and phosphinic acid analogs of DOTA.
ŠIMEČEK Jakub;
HERMANN Petr;
SEIDL C.;
MORGENSTERN Alfred;
NOTNI Johannes;
BRUCHERTSEIFER Frank;
WESTER Hans-Jürgen;
2014-08-04
SOC NUCLEAR MEDICINE INC
JRC88672
0161-5505,
https://publications.jrc.ec.europa.eu/repository/handle/JRC88672,
| Name | Country | City | Type |
|---|
This document is only visible at the Commission level.
You are not authorized to publish or distribute it outside the European Commission.
This is a public document. You can share this publication.
Datasets
| ID | Title | Public URL |
|---|
Dataset collections
| ID | Acronym | Title | Public URL |
|---|
Scripts / source codes
| Description | Public URL |
|---|
Additional supporting files
| File name | Description | File type |
|---|